Fujirebio Diagnostics Inc.
MALVERN, Pennsylvania, June 6, 2011 -
- Fujirebio Diagnostics' ROMA(TM) (HE4 + CA125) Test is Validated in the
Italian Population
A study recently published online in the journal Clinica Chimica Acta
validated the use of the HE4 test and the ROMA (Risk of Ovarian Malignancy
Algorithm) algorithm in distinguishing malignant from benign pelvic masses in
the Italian population.
MALVERN, Pennsylvania, May 31, 2011 -
- FDA Decision Clears Way for CYFRA 21-1(TM) to Monitor Disease
Progression in Patients with Lung Cancer
Fujirebio Diagnostics, Inc., today announced that the U.S.
